Living with Lymphoma

Chapter 1: What Is Lymphoma, and Why This Diagnosis Feels So Confusing

A doctor says the word "lymphoma," and the room seems to tilt. Maybe you came in for a swollen node you assumed was nothing, or a routine scan turned up something your doctor wanted to look at more closely. Whatever the path, you likely walked out with a diagnosis and almost no working knowledge of what it actually means. That gap between the seriousness of the word and your understanding of it is where most of the fear lives.

Lymphoma is a cancer that starts in lymphocytes, a type of white blood cell your immune system relies on to fight infection. B-cells and T-cells, the two main kinds of lymphocytes, normally patrol your body as part of the lymphatic system: a network of vessels, nodes, and organs (including the spleen and thymus) that filters fluid and coordinates your immune defenses. Lymphoma happens when one of these cells picks up damage that lets it grow and divide without the normal checks on cell growth. It builds up in lymph nodes and sometimes other tissue, and it can spread through the same channels your immune cells use to travel and protect you.

Because lymphocytes circulate through nearly your whole body, lymphoma is not confined to one organ the way, say, lung cancer starts in the lungs. That is part of what makes the diagnosis feel disorienting at first. It can turn up as a lump in your neck, a mass in your chest found on an unrelated X-ray, or fatigue and fevers with no obvious lump at all. The disease does not behave like the cancers most people picture, and the unfamiliarity adds to the shock.

Two Diseases Under One Name

The first thing worth untangling is that "lymphoma" is a category, split into two major groups: Hodgkin lymphoma and Non-Hodgkin lymphoma. They share a starting point, malignant lymphocytes, but from there they diverge in how they are identified, how common they are, who they tend to affect, and how they typically progress.

Hodgkin lymphoma (HL) has a defining feature: a distinctive, large abnormal cell called a Reed-Sternberg cell, visible under a microscope. Pathologists look for these cells specifically, and finding them is what confirms an HL diagnosis rather than NHL. Reed-Sternberg cells do not show up in Non-Hodgkin lymphoma, and that single difference is the dividing line between the two branches, even though both start with the same kind of cell going wrong.

Non-Hodgkin lymphoma (NHL) is the larger and far more varied group. Where HL is essentially one recognizable disease with a few subtypes, NHL covers more than 70 different subtypes, arising from either B-cells or T-cells, each with its own genetic fingerprint, growth pattern, and typical treatment path. Some NHL subtypes are indolent, meaning slow-growing, and may be watched rather than treated right away. Others are aggressive, growing quickly but often responding well to treatment, with many considered potentially curable. That range, from watching closely to starting treatment right away, is itself part of what NHL means, and it is covered in more depth in the chapter on watch-and-wait.

In the United States, roughly 82,000 new lymphoma cases are diagnosed each year, and the large majority of those are NHL rather than HL. If you have just been told you have Non-Hodgkin lymphoma, you are looking at the more common branch of a disease that is itself less common than many other cancers, which is one reason it can be harder to find people around you who have been through the same thing.

Who Tends to Get Which

The two branches also differ in who they typically affect, and the pattern for HL is worth naming directly. NHL's typical age at diagnosis is around the late 60s, following a pattern closer to what you would expect from most cancers, with risk climbing as people age. HL instead shows a bimodal pattern: one peak in young adults in their 20s to early 30s, then a second peak after age 55. Two separate age groups, same disease. Nobody fully understands why HL clusters this way, though researchers have looked closely at how immune development and certain viral exposures might play a role at each end of that range.

If you are 28 and just diagnosed with Hodgkin lymphoma, this age pattern means you are not an outlier or an unlucky exception to a disease of older adults. You are squarely inside one of its two expected windows. If you are 60, you are just as squarely inside the other one.

Why the Confusion Is Normal

It is worth saying plainly: the fog you feel right now is not a sign that you are bad at absorbing information. You are being asked to learn a new vocabulary (lymphocytes, nodes, staging, subtypes) at the exact moment your brain is least equipped to retain new vocabulary. Stress hormones interfere with memory formation. Grief interferes with focus. Most people forget the majority of what is said in the appointment where they are first told they have cancer, and oncology teams know this, which is why good ones repeat information across multiple visits rather than expecting it to land the first time.

The subtype and Hodgkin/Non-Hodgkin distinction matters because it shapes almost everything downstream. It affects what staging looks like, what watch-and-wait might mean for you specifically, which treatment classes your oncologist will discuss, and even what your prognosis conversation sounds like. You do not need to master any of that today. Right now, the useful task is smaller: understanding that lymphoma is a cancer of lymphocytes, that it splits into two major branches identified by a specific cell marker, and that the branch and subtype you have will determine the specifics your team walks you through next.

Figure 1: Use this to see where your own diagnosis fits before the next appointment fills in the specifics.

None of this changes in the hours after you hear it. What changes next is more specific: which branch you fall into and which of those 70-plus subtypes is actually yours, the subject of Chapter 2.

End of free sample. The full book picks up right where this leaves off.